Literature DB >> 22257127

Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.

Benjamin W Jester1, Alicia Gaj, Carolyn D Shomin, Kurt J Cox, Indraneel Ghosh.   

Abstract

Using a newly developed competitive binding assay dependent upon the reassembly of a split reporter protein, we have tested the promiscuity of a panel of reported kinase inhibitors against the AGC group. Many non-AGC targeted kinase inhibitors target multiple members of the AGC group. In general, structurally similar inhibitors consistently exhibited activity toward the same target as well as toward closely related kinases. The inhibition data was analyzed to test the predictive value of either using identity scores derived from residues within 6 Å of the active site or identity scores derived from the entire kinase domain. The results suggest that the active site identity in certain cases may be a stronger predictor of inhibitor promiscuity. The overall results provide general guidelines for establishing inhibitor selectivity as well as for the future design of inhibitors that either target or avoid AGC kinases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257127      PMCID: PMC3328412          DOI: 10.1021/jm201265f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  71 in total

1.  The discovery of potent cRaf1 kinase inhibitors.

Authors:  K Lackey; M Cory; R Davis; S V Frye; P A Harris; R N Hunter; D K Jung; O B McDonald; R W McNutt; M R Peel; R D Rutkowske; J M Veal; E R Wood
Journal:  Bioorg Med Chem Lett       Date:  2000-02-07       Impact factor: 2.823

Review 2.  Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks.

Authors:  James T Metz; Philip J Hajduk
Journal:  Curr Opin Chem Biol       Date:  2010-07-06       Impact factor: 8.822

Review 3.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  Selectivity of kinase inhibitor fragments.

Authors:  Paul Bamborough; Murray J Brown; John A Christopher; Chun-wa Chung; Geoff W Mellor
Journal:  J Med Chem       Date:  2011-06-23       Impact factor: 7.446

5.  Navigating the kinome.

Authors:  James T Metz; Eric F Johnson; Niru B Soni; Philip J Merta; Lemma Kifle; Philip J Hajduk
Journal:  Nat Chem Biol       Date:  2011-02-20       Impact factor: 15.040

6.  Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm.

Authors:  H Shimokawa; M Seto; N Katsumata; M Amano; T Kozai; T Yamawaki; K Kuwata; T Kandabashi; K Egashira; I Ikegaki; T Asano; K Kaibuchi; A Takeshita
Journal:  Cardiovasc Res       Date:  1999-09       Impact factor: 10.787

7.  SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

Authors:  D C Underwood; R R Osborn; C J Kotzer; J L Adams; J C Lee; E F Webb; D C Carpenter; S Bochnowicz; H C Thomas; D W Hay; D E Griswold
Journal:  J Pharmacol Exp Ther       Date:  2000-04       Impact factor: 4.030

8.  Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.

Authors:  Sudharshan Eathiraj; Rocio Palma; Erika Volckova; Marscha Hirschi; Dennis S France; Mark A Ashwell; Thomas C K Chan
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

9.  An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Authors:  J R Jackson; A Gilmartin; C Imburgia; J D Winkler; L A Marshall; A Roshak
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

10.  A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases.

Authors:  Benjamin W Jester; Kurt J Cox; Alicia Gaj; Carolyn D Shomin; Jason R Porter; Indraneel Ghosh
Journal:  J Am Chem Soc       Date:  2010-08-25       Impact factor: 15.419

View more
  11 in total

1.  Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors.

Authors:  Nis Halland; Friedemann Schmidt; Tilo Weiss; Joachim Saas; Ziyu Li; Jörg Czech; Matthias Dreyer; Armin Hofmeister; Katharina Mertsch; Uwe Dietz; Carsten Strübing; Marc Nazare
Journal:  ACS Med Chem Lett       Date:  2014-10-23       Impact factor: 4.345

2.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

3.  Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Authors:  Frank E Kwarcinski; Kristoffer R Brandvold; Sameer Phadke; Omar M Beleh; Taylor K Johnson; Jennifer L Meagher; Markus A Seeliger; Jeanne A Stuckey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2016-03-01       Impact factor: 5.100

4.  Exquisitely specific bisubstrate inhibitors of c-Src kinase.

Authors:  Kristoffer R Brandvold; Shana M Santos; Meghan E Breen; Eric J Lachacz; Michael E Steffey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

5.  Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.

Authors:  Christopher R M Asquith; Louisa Temme; Michael P East; Tuomo Laitinen; Julie Pickett; Frank E Kwarcinski; Parvathi Sinha; Carrow I Wells; Gary L Johnson; Reena Zutshi; David H Drewry
Journal:  ChemMedChem       Date:  2022-05-09       Impact factor: 3.540

6.  Biotinylated phosphoproteins from kinase-catalyzed biotinylation are stable to phosphatases: implications for phosphoproteomics.

Authors:  Chamara Senevirathne; Mary Kay H Pflum
Journal:  Chembiochem       Date:  2013-01-17       Impact factor: 3.164

7.  Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.

Authors:  Frank E Kwarcinski; Christel C Fox; Michael E Steffey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2012-09-05       Impact factor: 5.100

8.  New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.

Authors:  Man Wu; Hayley V White; Blake A Boehm; Christopher J Meriney; Kaylan Kerrigan; Michael Frasso; Mary Liang; Erika M Gotway; Madeleine R Wilcox; Jon W Johnson; Peter Wipf; Stephen D Meriney
Journal:  Neuropharmacology       Date:  2017-12-12       Impact factor: 5.250

9.  Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.

Authors:  Craig Fraser; John C Dawson; Reece Dowling; Douglas R Houston; Jason T Weiss; Alison F Munro; Morwenna Muir; Lea Harrington; Scott P Webster; Margaret C Frame; Valerie G Brunton; E Elizabeth Patton; Neil O Carragher; Asier Unciti-Broceta
Journal:  J Med Chem       Date:  2016-05-04       Impact factor: 7.446

10.  Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.

Authors:  John D Lapek; Patricia Greninger; Robert Morris; Arnaud Amzallag; Iulian Pruteanu-Malinici; Cyril H Benes; Wilhelm Haas
Journal:  Nat Biotechnol       Date:  2017-09-11       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.